Addex Therapeutics Ltd · SIX:ADXN

Addex Therapeutics — Investor Presentation (March 2017)

49 slides from Addex Therapeutics's investor presentation, Mar 1, 2017

  1. Slide 1: Addex Corporate Presentation

    Addex Corporate Presentation 1 March 2017 Innovative Treatments for Central Nervous System Disorders SIX: ADXN Allosteric modulators for human health

  2. Slide 2: Disclaimer

    Disclaimer • These materials do not constitute or form part, or all, of any offer or invitation to sell or issue, neither in the United States of America nor elsewhere, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their

  3. Slide 3: Investment Highlights

    Investment Highlights  Founded in 2002  Headquartered in Geneva Swiss Company  Traded on the SIX Swiss Stock Exchange since SIX Listed 2007 – ADXN  13.5M shares and market cap of CHF30M  FDA Orphan Drug Designation granted in PD-LID Dipraglurant for  Positive Phase 2 POC in PD-LID z Parkinson’

  4. Slide 4: Clinical Stage Pipeline with Registration Trial Ready Program

    Clinical Stage Pipeline with Registration Trial Ready Program Multiple orphan drug opportunities Phase 2B /3 Molecule / MoA Preclinical Phase 1 Phase 2 Pivotal Dipraglurant-IR mGluR5 NAM Parkinson’s disease levodopa induced dyskinesia Dipraglurant-ER mGluR5 NAM Focal cervical dystonia ADX71441 GABAB

  5. Slide 5: Extensive Preclinical Stage Pipeline for Long-Term Growth

    Extensive Preclinical Stage Pipeline for Long-Term Growth Molecule / Lead Clinical Hit to Lead Collaboration Partners MoA Optimization Candidate Parkinson’s disease, addiction, mGluR4 PAM autoimmune disease mGluR2 NAM Depression, stroke Endometriosis, uterine FSH / LH NAM fibrosis, polycystic ovaria

  6. Slide 6: Dipraglurant in Parkinson's Disease

    Dipraglurant in Parkinson’s Disease 6

  7. Slide 7: Levodopa-Induced Dyskinesia in Parkinson's Disease

    Levodopa-Induced Dyskinesia in Parkinson’s Disease A debilitating condition • Abnormal involuntary movement following levodopa dosing - problematic to patient and caregiver • Prevalence of LID is related to age, treatment and disease duration. • After 3 years of levodopa treatment LID experienced by

  8. Slide 8: Dipraglurant - Overview & Mechanism of Action in LID

    Dipraglurant - Overview & Mechanism of Action in LID Severe PD (advanced neuron degeneration) • Loss of substantia nigra neurons combined with the non-physiological, STRIATUM L-DOPA pulsatile, stimulation of dopamine L-dopa (drug) receptors are at the basis of LID Dopamine development DYSREGULATED D

  9. Slide 9: Dipraglurant PK is a Key Advantage for Treating LID

    Dipraglurant PK is a Key Advantage for Treating LID • Dyskinesia symptoms are correlated to peak levels of levodopa therapy • PK profile of dipraglurant mirrors DYSKINESIA that of levodopa • Dipraglurant inhibits abnormal glutamate stimulation during peak L-DOPA peak levodopa dose but releases the r

  10. Slide 10: Dipraglurant EU and US Phase 2A Study in LID

    Dipraglurant EU and US Phase 2A Study in LID Multicentre study in 25 centres across US and Europe N= 52 Dipraglurant  Primary objective: safety & tolerability  Secondary objective: N=76 exploratory efficacy Moderate to severe PD-LID R  Modified Abnormal Involuntary N=24 Movement Scale (mAIMS) at

  11. Slide 11: Dipraglurant Reduces LID Severity by 30% in LID Patients

    Dipraglurant Reduces LID Severity by 30% in LID Patients Change from baseline in peak mAIMS at 90 min • Dipraglurant had a statistically significant MMRM model, changes over time, FAS population effect in the first day • Dipraglurant reduced dyskinesia compared to placebo at all visits over the 28 d

  12. Slide 12: Clinician Rated Global Impression of Change - dyskinesia

    Clinician Rated Global Impression of Change - dyskinesia Greater improvement in dyskinesia with dipraglurant according to clinicians (p<0.05) Dipraglurant Placebo Improved (p<0.05) 71.2% 49.9% No change 17.3% 45.8% 12

  13. Slide 13: Patient Diaries – Improvement Throughout the Waking Day

    Patient Diaries – Improvement Throughout the Waking Day After 4-week treatment with dipraglurant: • ON time with LID reduced during the day • ON time without LID increased and maintained during the day 13

  14. Slide 14: Summary of Efficacy Data

    Summary of Efficacy Data • Dipraglurant showed a clinical meaningful improvement of dyskinesia – Significant improvement of mAIMS at Day 1 and Day 14 – Day 28 confounded by placebo response – Clinically meaningful and statistically significant (≥30% improvement) achieved by twice as many on active a

  15. Slide 15: Dipraglurant Doses Demonstrated Safety and Satisfactory Tolerability

    Dipraglurant 50 and 100 mg Doses Demonstrated Safety and Satisfactory Tolerability in PD Patients • Adverse events were common in both treatment groups (dipraglurant 88.5%, pbo 75%) • The majority of patients completed the dose escalation regimen • Most common AEs: • AEs caused discontinuation in 2

  16. Slide 16: mGlu5 Receptor Occupancy (PET) Data in Healthy Volunteers

    mGlu5 Receptor Occupancy (PET) Data in Healthy Volunteers N of subjects Dose (mg) % Receptor occupancy Mean ± SD 4* 100 27% ± 9% 4 200 44% ± 23% 4 300 53% ± 30% * Only 3 used for analysis because of lack of arterial sampling in one of the subjects • Demonstrates target engagement • mGlu5 receptor oc

  17. Slide 17: Clinical Development Plan

    Clinical Development Plan • Confirmatory trials: – Two studies required for registration • Primary endpoint: UDysRS - more sensitive to treatment effect (Goetz 2013) • Study 203 – 13 weeks; • Confirmatory Phase 3: Study 301 of 26 weeks (primary end point at 13 weeks) – Open label extension: 100 pati

  18. Slide 18: Management of Placebo Response

    Management of Placebo Response Objective Strategy Minimize rater variability Use independent (centralized) raters (across and within sites) Reduce expectancy bias Raters blinded to visit and do not rate the same patient at baseline and study endpoint Exclude patients with Ensure that symptom score r

  19. Slide 19: Study 203: Dipraglurant Phase 2B Pivotal Study in LID

    Study 203: Dipraglurant Phase 2B Pivotal Study in LID  Primary objective N= 255 N=85 Dipraglurant 200 mg t.i.d. efficacy in reducing LID Moderate to  Change over time in UDysRS severe PD-LID R N=85 Dipraglurant 100 mg t.i.d. (wk13 from baseline) patients N=85 Placebo  Secondary objective : safety

  20. Slide 20: Study 301: Dipraglurant Phase 3 Pivotal Study in LID

    Study 301: Dipraglurant Phase 3 Pivotal Study in LID  Primary objective: N=85 efficacy in reducing LID Dipraglurant Placebo  Change over time in UDysRS (w13 from baseline) N=170 Moderate to R  Secondary objective: severe PD-LID safety & tolerability, N= 85 additional efficacy Placebo Placebo para

  21. Slide 21: Summary – Dipraglurant LID opportunity

    Summary – Dipraglurant LID opportunity • LID is a large unmet need and market opportunity – 170K LID patients in US - $1.7B-$3.4B US market opportunity • Limited competition – Mavoglurant terminated – dipraglurant now 1st in class – ADS-5102: PDUFA date 24 Aug 17, but improvement over generic amanta

  22. Slide 22: Dipraglurant in Dystonia

    Dipraglurant in Dystonia fo} Q xe) [o} OQ e fe} 22

  23. Slide 23: Dystonia

    Dystonia • Dystonia is a neurological movement disorder – sustained muscle contractions cause twisting and repetitive movements or abnormal postures – It is the third most common movement disorder • Primary dystonia develop spontaneously in the absence of any apparent cause or associated disease – M

  24. Slide 24: Treatment Options for Dystonia

    Treatment Options for Dystonia • Deep brain stimulation for inherited/idiopathic dystonia (e.g. DYT1) – reduces severity of symptoms by approx. 50% – Invasive procedure – most patients are children • Botulinum toxin injections for focal dystonia (e.g. cervical dystonia) • Physical therapy and massag

  25. Slide 25: Dipraglurant Shows Consistent and Robust Preclinical and Clinical Efficacy in Dystonia Models

    Dipraglurant Shows Consistent and Robust Preclinical and Clinical Efficacy across a number of Dystonia models Dipraglurant efficacy in the dystonia component of L-Dopa Dipraglurant reduced severity of dystonia in the induced dyskinesia – PD-LID macaque PD-LID model Dipraglurant normalises altered sy

  26. Slide 26: Dipraglurant Phase 2a POC study in Focal Cervical Dystonia

    Dipraglurant Phase 2a POC study in Focal Cervical Dystonia Single-centre study, US Dipraglurant Placebo  Primary objective: N=18 efficacy BT R  Change from baseline in TWSTRS (a physician-rated Placebo Dipraglurant questionnaire that can be conducted live or via videotapes).  Videotape evaluation

  27. Slide 27: Dipraglurant Development Plans in Dystonia – Overview

    Dipraglurant Development Plans in Dystonia – Overview • US Phase 2a POC trial in focal cervical dystonia ready to start – Lead investigator- Prof. Jinnah of Emory University School of Medicine, Atlanta • Characterize dipraglurant in genetic forms of dystonia – Collaboration with Prof Pisani ongoing

  28. Slide 28: ADX71441-GABAB R Positive Allosteric Modulator

    ADX71441-GABABR Positive Allosteric Modulator 28

  29. Slide 29: ADX71441- First in Class & Clinically Validated Concept

    ADX71441- First in Class & Clinically Validated Concept • Mechanism of action: – positive allosteric modulator or the gamma-aminobutyric acid subtype B (GABAB) receptor • Novel, highly selective, orally bioavailable, brain penetrant, small molecule • Activation of GABAB receptor is preclinically, cl

  30. Slide 30: ADX71441 in Charcot-Marie-Tooth Type 1A Neuropathy

    ADX71441 in Charcot-Marie-Tooth Type 1A Neuropathy 30

  31. Slide 31: Rationale for ADX71441 in CMT1A

    Rationale for ADX71441 in CMT1A • Charcot Marie Tooth (CMT) disorder is one of the most common inherited neuropathy • Duplication of the peripheral myelin protein 22 gene causes the most frequent subtype - CMT1A. • CMT1A affects approximately 1 in 5,000 people worldwide.. • Over production of periph

  32. Slide 32: GABAB and CMT1A

    GABAB and CMT1A • GABAB has been shown to regulate the production of PMP-22 • Gene duplication of the pmp22 gene causes over production of peripheral myelin protein-22 (PMP-22), causing the structure and function of the myelin sheath to be abnormal. Cross Section of Axons Healthy 27 year old patient

  33. Slide 33: CMT1A Treatments Options and Development Pipeline

    CMT1A Treatments Options and Development Pipeline • Non-invasive therapies (e.g. exercise, physiotherapy, orthotics). • Surgery to straighten toes, lengthen heel cords or lower arches. • Drugs used off-label for the treatment of CMT1A include: – Anticonvulsants (e.g. Clonazepam and Gabapentin) to tr

  34. Slide 34: GABABR Activation Therapy with ADX71441 in CMT Rats

    GABABR Activation Therapy with ADX71441 in CMT Rats • CMT rats showed an overexpression of pmp22 mRNA, axonal loss and reduced grip strength reflecting typical CMT1A features • In a comparative study with baclofen in CMT1A rats, ADX71441 significantly reduced pmp22 mRNA at 3mg/kg and 6 mg/kg p.o. (0

  35. Slide 35: GABABR Activation Therapy with ADX71441 in CMT Rat Model

    GABABR Activation Therapy with ADX71441 in CMT Rat Model • CMT rats showed an overexpression of pmp22 mRNA, axonal loss and reduced grip strength reflecting typical CMT1A features • In a comparative study with baclofen in CMT1A rats, ADX71441 significantly reduced pmp22 mRNA at 3mg/kg and 6 mg/kg p.

  36. Slide 36: ADX71441 Development Plans in CMT1A – Overview

    ADX71441 Development Plans in CMT1A – Overview • Achieved: – Preclinical PoC in the CMT rat model • Ongoing: – Collaboration with the CMTA to further characterize ADX71441 includes: • Collaboration with Dr. John Svaren who is actively involved in the development of in vitro screening assays and biom

  37. Slide 37: ADX71441 in Addiction of Nicotine, Cocaine and Alcohol

    ADX71441 in Addiction of Nicotine, Cocaine and Alcohol 37

  38. Slide 38: Rationale for Developing ADX71441 in Addiction

    Rationale for Developing ADX71441 in Addiction • GABA is the major inhibitory neurotransmitter in the brain and is implicated in the modulation of central reward processes. • Administration of GABAB receptor agonists or positive modulators decreased self- administration of various drugs of abuse. •

  39. Slide 39: ADX71441 Collaboration Program with NIDA and NIAAA

    ADX71441 Collaboration Program with NIDA and NIAAA • Achieved: − Characterization in a battery of preclinical models for alcohol use disorders (NIAAA) − Preclinical PoC in a mouse nicotine model (NIDA) − Preclinical PoC in Part I of a non human primate model of cocaine addiction (NIDA) − Preclinical

  40. Slide 40: ADX71441 - Positive Results in Alcohol-related Behaviors

    ADX71441 - Positive Results in Alcohol-related Behaviors NIAAA Collaboration • Effect of ADX71441 on preclinical models of alcohol consumption – ADX71441 strongly reduces alcohol self administration and motivation to consume alcohol in rats. • Effect is dose dependent and statistically significant •

  41. Slide 41: Assessment of Potential Cocaine Treatment Medications in NHP

    Assessment of Potential Cocaine Treatment Medications in NHP • ADX71441 specifically reduced self-administration of cocaine at all doses (0.003 - 0.1mg/kg/injection) in monkeys • These results are quite remarkable and much better than those seen with baclofen. ATDP 33,600 = ADX71441 41

  42. Slide 42: ADX71441 Summary and Conclusion

    ADX71441 Summary and Conclusion • Strong rationale to develop a GABAB PAM that has a differentiated profile to baclofen: – GABAB PAM is clinically validated by data generated with baclofen, an orthosteric agonist of the GABAB receptor – ADX71441 has a differentiated preclinical profile to baclofen:

  43. Slide 43: Janssen Partnership ADX71149: mGluR2 PAM

    Janssen Partnership ADX71149: mGluR2 PAM Significant Potential in Treating CNS Disorders 43

  44. Slide 44: Overview of Janssen Partnership (ADX71149)

    Overview of Janssen Partnership (ADX71149) • ADX71149 is a highly selective oral brain penetrant small molecule metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator (PAM) discovered in collaboration with Janssen Pharmaceuticals Inc.(JPI) • mGluR2 PAM is validated in multiple indi

  45. Slide 45: Team, Financials & Milestones

    Team, Financials & Milestones 45

  46. Slide 46: Experienced Team

    Experienced Team • Executive Management: • Clinical advisors: – Tim Dyer, CEO / CFO – PD-LID • Co-founder of Addex, formerly with PwC • Michael J. Fox Foundation for Parkinson’s – Roger Mills, CMO Research • Formerly with Acadia Pharmaceuticals • Dr. Erwan Bézard • Prof Chris Goetz – Sonia Poli, CSO

  47. Slide 47: Financials and Stock

    Financials and Stock • Cash runway through 2018 – CHF3.9M million in cash as of 28 February 2017 • Traded on SIX Swiss Exchange: ADXN (ISIN:CH0029850754) • 13,454,553 shares outstanding (15 million fully diluted) – Herculis Partners holds 3.5% – Management & board holds 10% • Analyst coverage: – Lif

  48. Slide 48: Milestones

    Milestones Milestone Timing Dipragluant – LID Dipraglurant Phase 2b in LID – start dosing H1 2018 Dipraglurant Phase 2b study in LID – results H2 2019 Dipraglurant Phase 3 study in LID – start dosing H1 2020 Dipraglurant Phase 3 study in LID – results H2 2021 Dipragluant – Dystonia Dipraglurant Phas

  49. Slide 49: Allosteric modulators for human health

    Allosteric modulators for human health www.addextherapeutics.com 49

Addex Therapeutics — Investor Presentation (March 2017) on 6ix